Contributions
Abstract: P1906
Type: Poster
Abstract Category: Late breaking news
Background: Neurofilament light chain (NF-L) has been proposed as potential biomarker of disease activity in different conditions, including multiple sclerosis (MS) and clinically isolated syndrome (CIS). The strong correlation between cerebrospinal fluid and serum NF-L levels, detected with ultrasensitive single-molecule array, supports their value in monitoring tissue damage and treatment response. Although considered a clinically useful biomarker in demyelinating disorders, serum NF-L concentration has never been investigated in patients with neuromyelitis optica spectrum disorders (NMOSD) accordingly to antibodies status.
Goals: Analyse serum NF-L in patients with NMOSD and related disorders and compare their levels in cases with autoantibodies to Aquaporin-4 (AQP4-Ab), myelin oligodendrocyte antibodies (MOG-Ab) and seronegative subjects.
Methods: Patients were classified in five diagnostic categories:
1) NMOSD
2) idiopathic optic neuritis (ON);
3) idiopathic acute myelitis (AM);
4) idiopathic myelitis and optic neuritis;
5) polyfocal CIS.
As controls we included 25 patients with MS and 14 healthy subjects. Cell-based assay was used for the analysis of serum AQP4-Ab and MOG-Ab and ultrasensitive electrochemiluminescence immunoassay (Meso Scale Discovery QuickPlex SQ 120) for NF-L detection.
Results: Median NF-L levels were increased in 25 AQP4-Ab positive subjects (59 pg/ml, range 12-994) as compared to 22 MOG-Ab positive cases (25 pg/ml, range 12-140), 52 seronegative patients (18 pg/ml, range 12-540), 25 MS patients (12 pg/ml range 12-1464) and 14 healthy controls (12 pg/ml range 12-788).
Conclusions: Increased serum levels of NF-L in patients with MOG-Ab and, prominently, AQP4-Ab NMOSD and related disorders might reflect an ongoing axonal damage and a more malignant disease course.
Disclosure: Fundings: Sara Mariotto is currently supported by a research fellowship of the European Academy of Neurology. Markus Reindl is supported by a research Grant from the Austrian Federal Ministry of Science and Economy (grant BIG WIG MS).
Declaration of conflicting interests:
Alberto Gajofatto received speaking honoraria and travel support to attend scientific meeting by Merck and Novartis. Ruggero Capra received lecture fees from Novartis, Biogen, Teva, Genzyme and Sanofi-Aventis. The University Hospital, and Medical University of Innsbruck (Austria, Markus Reindl) receives payments for antibody assays (NMDAR, AQP4, and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Luebeck, Germany). Markus Reindl is an academic editor for PLoS One. The other authors declare that there is no conflict of interests.
Abstract: P1906
Type: Poster
Abstract Category: Late breaking news
Background: Neurofilament light chain (NF-L) has been proposed as potential biomarker of disease activity in different conditions, including multiple sclerosis (MS) and clinically isolated syndrome (CIS). The strong correlation between cerebrospinal fluid and serum NF-L levels, detected with ultrasensitive single-molecule array, supports their value in monitoring tissue damage and treatment response. Although considered a clinically useful biomarker in demyelinating disorders, serum NF-L concentration has never been investigated in patients with neuromyelitis optica spectrum disorders (NMOSD) accordingly to antibodies status.
Goals: Analyse serum NF-L in patients with NMOSD and related disorders and compare their levels in cases with autoantibodies to Aquaporin-4 (AQP4-Ab), myelin oligodendrocyte antibodies (MOG-Ab) and seronegative subjects.
Methods: Patients were classified in five diagnostic categories:
1) NMOSD
2) idiopathic optic neuritis (ON);
3) idiopathic acute myelitis (AM);
4) idiopathic myelitis and optic neuritis;
5) polyfocal CIS.
As controls we included 25 patients with MS and 14 healthy subjects. Cell-based assay was used for the analysis of serum AQP4-Ab and MOG-Ab and ultrasensitive electrochemiluminescence immunoassay (Meso Scale Discovery QuickPlex SQ 120) for NF-L detection.
Results: Median NF-L levels were increased in 25 AQP4-Ab positive subjects (59 pg/ml, range 12-994) as compared to 22 MOG-Ab positive cases (25 pg/ml, range 12-140), 52 seronegative patients (18 pg/ml, range 12-540), 25 MS patients (12 pg/ml range 12-1464) and 14 healthy controls (12 pg/ml range 12-788).
Conclusions: Increased serum levels of NF-L in patients with MOG-Ab and, prominently, AQP4-Ab NMOSD and related disorders might reflect an ongoing axonal damage and a more malignant disease course.
Disclosure: Fundings: Sara Mariotto is currently supported by a research fellowship of the European Academy of Neurology. Markus Reindl is supported by a research Grant from the Austrian Federal Ministry of Science and Economy (grant BIG WIG MS).
Declaration of conflicting interests:
Alberto Gajofatto received speaking honoraria and travel support to attend scientific meeting by Merck and Novartis. Ruggero Capra received lecture fees from Novartis, Biogen, Teva, Genzyme and Sanofi-Aventis. The University Hospital, and Medical University of Innsbruck (Austria, Markus Reindl) receives payments for antibody assays (NMDAR, AQP4, and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Luebeck, Germany). Markus Reindl is an academic editor for PLoS One. The other authors declare that there is no conflict of interests.